Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$62.0 - $79.01 $5.89 Million - $7.5 Million
-94,960 Closed
0 $0
Q2 2024

Aug 14, 2024

BUY
$22.0 - $69.71 $2.09 Million - $6.62 Million
94,960 New
94,960 $6.36 Million
Q4 2023

Oct 21, 2024

SELL
$23.42 - $31.74 $1.55 Million - $2.1 Million
-66,206 Reduced 62.49%
39,743 $1.23 Million
Q4 2023

Feb 07, 2024

SELL
$23.42 - $31.74 $1.55 Million - $2.1 Million
-66,206 Reduced 62.49%
39,743 $1.23 Million
Q3 2023

Oct 21, 2024

BUY
$19.86 - $26.93 $858,627 - $1.16 Million
43,234 Added 68.94%
105,949 $2.68 Million
Q3 2023

Nov 07, 2023

BUY
$19.86 - $26.93 $858,627 - $1.16 Million
43,234 Added 68.94%
105,949 $2.68 Million
Q2 2023

Oct 21, 2024

SELL
$16.44 - $21.1 $530,107 - $680,369
-32,245 Reduced 33.96%
62,715 $1.32 Million
Q2 2023

Aug 07, 2023

BUY
$16.44 - $21.1 $1.03 Million - $1.32 Million
62,715 New
62,715 $1.32 Million
Q4 2022

Feb 13, 2023

SELL
$16.98 - $23.15 $620,143 - $845,484
-36,522 Reduced 33.5%
72,490 $1.45 Million
Q3 2022

Nov 07, 2022

BUY
$20.88 - $28.21 $1.24 Million - $1.67 Million
59,195 Added 118.82%
109,012 $2.35 Million
Q2 2022

Aug 09, 2022

SELL
$17.07 - $25.71 $870,279 - $1.31 Million
-50,983 Reduced 50.58%
49,817 $983,000
Q1 2022

May 12, 2022

BUY
$20.42 - $28.13 $1.28 Million - $1.76 Million
62,560 Added 163.6%
100,800 $2.37 Million
Q4 2021

Feb 10, 2022

BUY
$25.89 - $33.45 $360,906 - $466,293
13,940 Added 57.37%
38,240 $1.04 Million
Q3 2021

Nov 12, 2021

BUY
$22.46 - $29.47 $545,778 - $716,121
24,300 New
24,300 $669,000

Others Institutions Holding INSM

About INSMED Inc


  • Ticker INSM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 135,476,992
  • Market Cap $9.56B
  • Description
  • Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...
More about INSM
Track This Portfolio

Track Jump Financial, LLC Portfolio

Follow Jump Financial, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jump Financial, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jump Financial, LLC with notifications on news.